Congestive heart failure myocardial viability study: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
| (24 intermediate revisions by 10 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{| class="infobox" style="float:right;" | |||
|- | |||
| [[File:Siren.gif|30px|link= Heart failure resident survival guide]]|| <br> || <br> | |||
| [[Heart failure resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
{{Congestive heart failure}} | {{Congestive heart failure}} | ||
{{CMG}}; {{AOEIC}} {{LG}} | {{CMG}}; {{AOEIC}} {{Sara.Zand}} {{LG}} | ||
==Overview== | ==Overview== | ||
[[Single-photon emission CT ]] ([[SPECT]]) can also be used to assess [[myocardial ischemia]] and [[viability]], [[myocardial inflammation]] or [[infiltration]]. | |||
[[Scintigraphy]] with [[technetium]] ([[Tc]])-labeled bisphosphonate has shown high sensitivity and specificity for imaging [[cardiac transthyretin amyloid]]. | |||
==Myocardial Viability Studies== | |||
Common imaging modalities to assess myocardial viability include: | |||
*[[Dobutamine]] [[echocardiography]] | |||
*Nuclear tests ([[Single photon emission computed tomography|SPECT]] or [[Positron emission tomography|PET]]) | |||
*[[Cardiovascular magnetic resonance imaging (CMR)|Cardiac MRI]] | |||
===2021 European Society of Cardiology Guidelines (DO NOT EDIT) <ref name="pmid34447992">{{cite journal |vauthors=McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A |title=2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure |journal=Eur Heart J |volume=42 |issue=36 |pages=3599–3726 |date=September 2021 |pmid=34447992 |doi=10.1093/eurheartj/ehab368 |url=}}</ref>=== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ESC guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>Non-invasive stress imaging ([[CMR]], [[stress echocardiography]], [[SPECT]], [[PET]]) may be considered for the assessment of [[myocardial ischemia]] and viability in [[patients]] with [[CAD]] who are considered suitable for [[coronary revascularization]]. ''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>. [[Exercise testing]] may be considered to detect reversible [[myocardial ischemia]] and investigate the cause of [[dyspnea]]''([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | |||
|} | |||
===2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) <ref name="pmid35363500">{{cite journal| author=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM | display-authors=etal| title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2022 | volume= 145 | issue= 18 | pages= e876-e894 | pmid=35363500 | doi=10.1161/CIR.0000000000001062 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35363500 }} </ref> === | |||
{|class="wikitable" style="width:80%" | |||
: | |- | ||
: | |colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
= | |- | ||
{{ | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''6.''' In [[patients]] with [[HF]], an evaluation for possible [[ischemic heart disease]] can be useful to identify the cause and guide [[management]]. <ref name="pmid16098295">{{cite journal| author=Elhendy A, Sozzi F, van Domburg RT, Bax JJ, Schinkel AF, Roelandt JR | display-authors=etal| title=Effect of myocardial ischemia during dobutamine stress echocardiography on cardiac mortality in patients with heart failure secondary to ischemic cardiomyopathy. | journal=Am J Cardiol | year= 2005 | volume= 96 | issue= 4 | pages= 469-73 | pmid=16098295 | doi=10.1016/j.amjcard.2005.04.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16098295 }} </ref><ref name="pmid15077089">{{cite journal| author=Miller WL, Hodge DO, Tointon SK, Rodeheffer RJ, Nelson SM, Gibbons RJ| title=Relationship of myocardial perfusion imaging findings to outcome of patients with heart failure and suspected ischemic heart disease. | journal=Am Heart J | year= 2004 | volume= 147 | issue= 4 | pages= 714-20 | pmid=15077089 | doi=10.1016/j.ahj.2003.10.045 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15077089 }} </ref><ref name="pmid32588042">{{cite journal| author=Chow BJW, Coyle D, Hossain A, Laine M, Hanninen H, Ukkonen H | display-authors=etal| title=Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). | journal=Eur Heart J Cardiovasc Imaging | year= 2021 | volume= 22 | issue= 9 | pages= 1083-1090 | pmid=32588042 | doi=10.1093/ehjci/jeaa109 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32588042 }} </ref><ref name="pmid28798192">{{cite journal| author=Ferreira JP, Rossignol P, Demissei B, Sharma A, Girerd N, Anker SD | display-authors=etal| title=Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. | journal=Heart | year= 2018 | volume= 104 | issue= 7 | pages= 606-613 | pmid=28798192 | doi=10.1136/heartjnl-2017-311750 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28798192 }} </ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B-NR]])'' <nowiki>"</nowiki> | ||
=== | |||
|} | |||
==Related Chapters== | ==Related Chapters== | ||
| Line 25: | Line 49: | ||
*[[Exercise stress testing#Techniques used to Assess Myocardial Viability|Techniques used to Assess Myocardial Viability]] | *[[Exercise stress testing#Techniques used to Assess Myocardial Viability|Techniques used to Assess Myocardial Viability]] | ||
== | ==External Link== | ||
*[ | *[https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000001063.full.pdf 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]<ref name="pmid35363499">{{cite journal |vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW |title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines |journal=Circulation |volume=145 |issue=18 |pages=e895–e1032 |date=May 2022 |pmid=35363499 |doi=10.1161/CIR.0000000000001063 |url=}} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Cardiology]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Intensive care medicine]] | |||
[[Category:Medicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Up-To-Date cardiology]] | |||
Latest revision as of 20:48, 22 June 2022
 |
Resident Survival Guide |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Sara Zand, M.D.[2] Lakshmi Gopalakrishnan, M.B.B.S. [3]
Overview
Single-photon emission CT (SPECT) can also be used to assess myocardial ischemia and viability, myocardial inflammation or infiltration. Scintigraphy with technetium (Tc)-labeled bisphosphonate has shown high sensitivity and specificity for imaging cardiac transthyretin amyloid.
Myocardial Viability Studies
Common imaging modalities to assess myocardial viability include:
- Dobutamine echocardiography
- Nuclear tests (SPECT or PET)
- Cardiac MRI
2021 European Society of Cardiology Guidelines (DO NOT EDIT) [1]
| Class IIb |
| "Non-invasive stress imaging (CMR, stress echocardiography, SPECT, PET) may be considered for the assessment of myocardial ischemia and viability in patients with CAD who are considered suitable for coronary revascularization. (Level of Evidence: B) " |
| ". Exercise testing may be considered to detect reversible myocardial ischemia and investigate the cause of dyspnea(Level of Evidence: C) " |
2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) [2]
| Class IIa |
| "6. In patients with HF, an evaluation for possible ischemic heart disease can be useful to identify the cause and guide management. [3][4][5][6] (Level of Evidence:B-NR) " |
Related Chapters
External Link
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[7]
References
- ↑ McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland J, Coats A, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam C, Lyon AR, McMurray J, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano G, Ruschitzka F, Kathrine Skibelund A (September 2021). "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure". Eur Heart J. 42 (36): 3599–3726. doi:10.1093/eurheartj/ehab368. PMID 34447992 Check
|pmid=value (help). Vancouver style error: initials (help) - ↑ Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM; et al. (2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (18): e876–e894. doi:10.1161/CIR.0000000000001062. PMID 35363500 Check
|pmid=value (help). - ↑ Elhendy A, Sozzi F, van Domburg RT, Bax JJ, Schinkel AF, Roelandt JR; et al. (2005). "Effect of myocardial ischemia during dobutamine stress echocardiography on cardiac mortality in patients with heart failure secondary to ischemic cardiomyopathy". Am J Cardiol. 96 (4): 469–73. doi:10.1016/j.amjcard.2005.04.004. PMID 16098295.
- ↑ Miller WL, Hodge DO, Tointon SK, Rodeheffer RJ, Nelson SM, Gibbons RJ (2004). "Relationship of myocardial perfusion imaging findings to outcome of patients with heart failure and suspected ischemic heart disease". Am Heart J. 147 (4): 714–20. doi:10.1016/j.ahj.2003.10.045. PMID 15077089.
- ↑ Chow BJW, Coyle D, Hossain A, Laine M, Hanninen H, Ukkonen H; et al. (2021). "Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C)". Eur Heart J Cardiovasc Imaging. 22 (9): 1083–1090. doi:10.1093/ehjci/jeaa109. PMID 32588042 Check
|pmid=value (help). - ↑ Ferreira JP, Rossignol P, Demissei B, Sharma A, Girerd N, Anker SD; et al. (2018). "Coronary angiography in worsening heart failure: determinants, findings and prognostic implications". Heart. 104 (7): 606–613. doi:10.1136/heartjnl-2017-311750. PMID 28798192.
- ↑ Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (May 2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (18): e895–e1032. doi:10.1161/CIR.0000000000001063. PMID 35363499 Check
|pmid=value (help).